Keywords: TCRT stock, Alaunos Therapeutics, Velaris Therapeutics, ActRII-Fc, pulmonary arterial hypertension stocks, biotech private placement, Fairmount, Reverse merger biotech, premarket movers

What Happened

Alaunos Therapeutics, Inc. jumped nearly 189% on Tuesday to close at $3.03, with Volume exploding past 250 million shares and an intraday high of $4.32. The catalyst came in two parts: the company completed its Acquisition of privately held Velaris Therapeutics, and at the same time closed an oversubscribed private Placement of about $350 million. Pre-market today the stock was up more than 20% near $3.69, extending the momentum.

The Pipeline and the Cash

Velaris brings a portfolio of ActRII-Fc ligand traps and complementary biologics. They are designed to address the signaling imbalances that drive remodeling of lung blood vessels in pulmonary arterial hypertension (PAH) and related cardiopulmonary conditions. The programs are still pre-clinical. Management expects proof-of-concept data for VLR199 in 2028, and the funding also covers data for VLR360 and initial regulatory filings for VLR247 and VLR258.

The financing was led by Fairmount and included Venrock, T. Rowe Price, Wellington, Janus Henderson and others. It is expected to fund operations into 2029, and Peter Harwin of Fairmount joins the Alaunos board.

What Investors Should Weigh

The deal was stock-for-stock, with Velaris holders receiving common stock and new non-voting Series C convertible preferred. Each Series C share converts into 1,000 common shares, subject to ownership limits. The private placement priced at $1.4357 per common share equivalent, less than half of the $3.03 close, so new investors sit on a large gain. Executives and directors face 180-day lock-ups, but the terms also call for a resale registration statement, which could add shares to the market over time.

This is a classic biotech reset. A previously struggling company is now valued on a new clinical pipeline and substantial cash, but the science is early and the first meaningful data is about two years away. Investors should also remember that the shares more than doubled in a day on volume that dwarfs normal trading, so the price can swing sharply while new holders and the wider market settle on a value.

Key Highlights

  • Shares surge 189% to $3.03: Volume passed 250 million shares and the stock traded as high as $4.32.
  • $350 million raised: Fairmount led, with Venrock, T. Rowe Price, Wellington and Janus Henderson, funding operations into 2029.
  • Pipeline reset: Velaris adds PAH-focused ActRII-Fc ligand traps, with VLR199 proof-of-concept data expected in 2028.
  • Priced below market: The placement priced at $1.4357 per share equivalent, under half the closing price.
  • Pre-market extension: Shares were up more than 20% near $3.69 today.

Company Overview

Alaunos Therapeutics, Inc. is a Fort Lauderdale, Florida-based biotechnology company listed on Nasdaq. It was previously known for T-cell receptor therapies aimed at solid tumors and also holds a legacy pre-clinical obesity program. With Velaris, its focus shifts to PAH, a disease in which pressure rises in the lung arteries and strains the heart. As a development-stage biotech with no approved product, Alaunos does not earn sales today. Value would come from moving drugs through trials and then partnering, selling or launching them after approval. Until then, the company depends on investor funding such as this placement.

Disclaimer: This content is for information only and is not financial advice or a recommendation to buy or sell any security. Micro-cap and small-cap stocks carry high risk, including loss of capital. Prices reflect the data supplied and may change. Please do your own research or consult a licensed adviser.